Drug Profile
Seltorexant - Janssen Research & Development/Minerva Neurosciences
Alternative Names: JNJ-42847922; JNJ-7922; MIN-202Latest Information Update: 08 Apr 2024
Price :
$50
*
At a glance
- Originator Janssen Research & Development
- Developer Janssen Research & Development; Minerva Neurosciences
- Class Antidepressants; Fluorinated hydrocarbons; Ketones; Pyrimidines; Pyrroles; Sleep disorder therapies; Small molecules; Triazoles
- Mechanism of Action Orexin receptor type 2 antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Major depressive disorder
- Phase II Alzheimer's disease; Insomnia
- No development reported Sleep apnoea syndrome
Most Recent Events
- 10 Nov 2023 Janssen Research & Development completes the phase II trial in Alzheimer's Disease (In adults, In the elderly) in USA (PO, Tablet) (NCT05307692)
- 03 Oct 2023 Janssen Research & Development completes a phase III trial in Major depressive disorder (Adjunctive treatment, Treatment-experienced) in Belgium, Canada, Latvia, Lithuania, Serbia, United Kingdom, Argentina, Slovakia, Ukraine, Poland, Russia, Bulgaria, USA, Czech Republic and Malaysia (PO, Tablet) (EudraCT2020-000341-14) (NCT04513912)
- 28 Aug 2023 No recent reports of development identified for phase-I development in Major depressive disorder(Adjunctive treatment) in Belgium (PO)